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Highlights 
• ETV has good long term efficacy in adults with hydrocephalus, with a low risk of complications 
(6%). 
• Patients with a prior shunt have a higher risk of ETV failure.  
• ETV is a first-line treatment in patients with tectal gliomas.  
• Although most ETV failures occur within 2 years, long-term failures can also occur and recurrent 
symptoms should prompt neurosurgical workup. 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Abstract 
Objectives. To describe long-term outcomes of endoscopic third ventriculostomy (ETV) in adults with 
hydrocephalus.  
Methods. Single-institution retrospective review of adults treated with an ETV between 1998-2006. Patient 
demographics, treatment and follow-up data was collected. Patients were divided into two groups: primary 
ETV for previously untreated or newly diagnosed hydrocephalus; and secondary ETV in patients with prior 
shunts presenting with shunt malfunction. ETV outcome was deemed as successful if patients remained 
shunt-free after ETV. Multivariate analysis was performed using Cox regression.  
Results. 190 patients were included. Median age: 43 (range 16-79) years. Median follow-up period: 112 
(range 1-190) months. The primary and secondary ETV groups contained 129 and 61 patients, respectively. 
Operative complications occurred in 11 patients (6%). A successful outcome was obtained in 139 patients 
(73%). ETV failure occurred in 51 patients and the median time to failure was 2 (range 0-124) months. 
Although the majority (86%) of ETV failures occurred within 2 years postoperatively, failure was noted in 3 
cases between 5-10 years after intervention, including one patient who at 124 months follow-up. In 
multivariate analysis, only previous shunt was found to influence outcomes (p = 0.021), with a shorter ETV 
survival noted in patients with a prior shunt. Age, indication and ETV success score, did not influence 
outcome.  
  
Conclusions. ETV is a safe procedure with excellent rates of long-term efficacy. However, late failure can 
occur and patients should be instructed to seek medical advice if symptoms reoccur. Prior shunt is associated 
with a higher ETV failure rate.  
Key words 
Hydrocephalus; endoscopic third ventriculostomy; shunt; long-term outcomes.   
Running title 
Long-term ETV outcomes in adults  
Abbreviations  
ETV = endoscopic third ventriculostomy; LOVA = long-standing overt ventriculomegaly in adults.  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Introduction 
Endoscopic third ventriculostomy (ETV) was first performed by Mixter in 1923 and has since become an 
established treatment modality for obstructive hydrocephalus in children.1 However, its efficacy depends on 
several factors including indication, whether patients have previously received a shunt and patient age. Age 
is a particularly important factor as rates of CSF reabsorption appear to decrease with increasing age, such 
that the efficacy of ventriculostomy, which diverts CSF to the subarachnoid space through a fistula in the 
third ventricle floor, may decrease with age.2-4 However, studies reporting long-term efficacy in adults are 
generally sparse and limited by sample size. We have previously reported our institutional experience with 
ETV in adults.5 In this study, we report our updated experience with longer-term outcomes.  
Methods 
Study population 
The institutional review board approved this study. Adult (≥16 years) patients who underwent an ETV at our 
institution (The Walton Centre Foundation Trust, Liverpool, UK) between April 1998 to August 2007 were 
included for case-notes review. Data was collected pertaining to patient demographics, cause of 
hydrocephalus, ETV indication, operative complications and follow-up treatment. The aetiology of 
hydrocephalus was classified as aqueduct stenosis, long-standing overt ventriculomegaly in adults (LOVA), 
tumour, Chiari malformation and others. The ETV success score was also calculated for each patient as 
previously described.6 Patients were divided into two ETV groups: primary ETV for previously untreated or 
newly diagnosed hydrocephalus; and secondary ETV in patients with prior shunts presenting with shunt 
malfunction. 
Procedure 
The operative technique has been previously described.5, 7 Briefly, patients were placed supine, with head 
flexed at 10°. A right precoronal burr hole was created 3cm from the midline. An introducing catheter was 
inserted into the right lateral ventricle to a depth of 4-5 cm, and the inner sleeve was withdrawn. A variety of 
endoscopes were used including flexible and rigid instruments. The endoscope was inserted and guided 
through the foramen of Monro into the third ventricle. A light-touch balloon (NMT Neurosciences) was used 
to fenestrate the floor midway between the infundibulum and mammillary bodies. Appearances of the third 
ventricle are demonstrated in Fig. 1. The fenestration was entered to inspect the prepontine space, to confirm 
a clear path to the subarachnoid space. If multiple membranes were encountered, these were also fenestrated. 
The cortical hole left by the endoscope was plugged with thick Spongostan (Johnson & Johnson) to avoid 
CSF leakage into the subdural space and the wound was closed. In cases of shunt malfunction, the shunt was 
removed in its entirety unless it was deemed to be so old or embedded that it was dangerous to do so. Other 
ventricular access devices (e.g. EVD or CSF reservoirs) were not routinely inserted at the time of ETV. 
Statistics and outcomes 
Statistics were performed using SPSS version 21 (SPSS Inc., Chicago, USA). ETV outcome was deemed as 
successful if patients remained shunt-independent after ETV placement. ETV survival was calculated in 
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months from the date of surgery to the date of shunt placement, or censored at the date of last follow-up if 
the patient remained shunt-independent. Survival analysis was used to determine the effect of the following 
on ETV success: age (≤ vs. >median age), presence of previous shunt, indication and ETV success score 
(≥80 vs. <80). Univariate analysis was performed using Kaplan Meier survival curves and the log-rank test. 
Multivariate analysis was performed using a forward stepwise cox regression model, including variables 
where p<0.1 in univariate analysis.  
Results 
Patient characteristics 
190 patients underwent an ETV procedure during the study period. The median patient age was 43 years 
(range 16-79 years) years and the median follow-up period was 112 (range 1-190) months. The primary ETV 
group contained 129 patients and the secondary ETV group contained 61 patients. The primary ETV group 
was older on average (mean age 45 vs. 36 years, independent t-test, t = 3.692, p < 0.001). Patients in the 
secondary group had failure of ventriculoperitoneal (n = 56, 92%) or ventriculoatrial (n = 5, 8%) shunts.  
Complications and mortality 
Operative complications occurred in 11 (6%) patients, including three cases of procedure abandonment due 
to abnormal anatomy (n = 2) or profuse bleeding (n = 1). Other complications included minor intraoperative 
haemorrhage (n = 2), CSF leak (n = 2), asymptomatic subdural haematomas (n = 2) and transient abducens 
palsy (n = 2). None of these 11 patients had early (<1 month) postoperative mortality. There were 42 deaths 
during the follow-up period and the majority were in the primary ETV group (n = 34, 81%). Cause of death 
data could not be obtained. Overall mortality rates were 26% and 13%, in the primary and secondary ETV 
groups, respectively.  
Repeat ETV procedures 
15 patients required either one or more repeat ETV procedures. All patients had evidence of complete or 
partial closure of the ventriculostomy site on dynamic CSF-MRI flow studies. The commonest underlying 
pathology in patients undergoing a repeat procedure included tumour/colloid cyst (n = 5) and LOVA (n = 4). 
The proportion of patients undergoing a repeat procedure was similar between the primary and secondary 
groups (6% vs. 12%, Fisher’s Exact, p = 0.251). In the repeat ETV cohort, 9 patients (60%) remain shunt-
free. A repeat procedure was performed at a median of 39 (range 1-163) months after the first procedure. 
Two patients required a second repeat procedure at range of 15-19 months after the first and one remains 
shunt-free.  
Shunt-independence 
A successful ETV outcome was obtained in 139 patients (73%). The ETV success rate in each group is 
shown in Table 1. The primary ETV group had a higher rate of ETV success (Fisher’s exact, p = 0.005). ETV 
survival was longer in the primary ETV group (log-rank = 8.444, p = 0.004) (Table 3 and Fig. 2A). 
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ETV failure occurred in 51 patients and the median time to ETV failure was 2 (range 0-124) months. The 
majority of failures (44/51, 86%) occurred within the first two years of operation. There were 7 cases of 
failure beyond this timeframe, including 4 between 2-5 years postoperatively and 3 between 5-10 years 
postoperatively. The 5-10 year group included one patient who re-presented with symptoms of 
hydrocephalus after 124 months (10 years) follow-up. The time to ETV failure was not significantly different 
between the groups (11 vs. 13, independent t-test, t = 0.264, p = 0.793). In the cohort of patients with an ETV 
survival time of 2 years or more, there were only 7 failures out of 118 patients (Fig. 2B). Most of these 
failures occurred in the secondary ETV group (5 vs. 2, log-rank = 5.230, p = 0.022). 
Aetiology 
Rates of shunt-independence within each ETV group, stratified by cause, are shown in Table 2 and illustrated 
in Fig. 3. The most common primary and secondary indications for an ETV were tumour and shunt blockage, 
in 51% and 85% of patients, respectively. In the primary ETV group, success rates by diagnosis were as 
follows: aqueduct stenosis 89%, LOVA 83%, chiari malformations 89%, tumours 76%. Other primary causes 
had an overall success rate of 82%. In the secondary ETV group, success rates by underlying indication were 
62% for mechanical shunt blockage and 44% for shunt infection. 
Outcomes  
In univariate analysis, younger age (log-rank = 4.091, p = 0.043), previous shunt (log-rank = 8.444, p = 
0.004) and post-infectious aetiology were associated with a shorter duration of ETV survival. Other factors 
did not influence outcome: ETV success score (log-rank = 0.075, p = 0.784), or indications for ETV such as 
tumour  (log-rank = 0.217, p = 0.641), aqueduct stenosis or LOVA (log-rank = 0.888, p = 0.346), chiari and 
spina bifida (log-rank = 0.539, p = 0.463) and post-haemorrhagic hydrocephalus (log-rank = 0.186, p = 
0.666). For multivariate cox regression, post-infectious aetiology was excluded due to significant bias of 
group sizes. At the multivariate level, previous shunt (p = 0.021; HR = 1.946, 95% CI 1.108 - 3.419), but not 
age (p = 0.146; HR = 0.646, 95% CI 0.358 - 1.165), was found to influence outcome.  
Discussion 
In this study, we have updated our ETV experience and presented outcomes after long-term follow-up. In our 
cohort of patients with hydrocephalus of various aetiologies, an ETV was used as first-line treatment in most 
(68%) cases, with only a minority (32%) receiving it after shunt-failure. After long-term follow-up (median 
112 months), a successful ETV outcome was obtained in 139 patients (73%), which is a 5% drop compared 
to our previous report.5 Indeed, although the vast majority (86%) of ETV failures occurred within 2-years of 
the procedure, late failures (>5 years) were noted in a handful (three) of cases, including one that occurred up 
to 10 years postoperatively. Finally, using multivariate analysis, we found that previous shunt was the only 
factor that predicted outcome in adults with ETV.  
Long-term efficacy 
Studies that have reported outcomes with ETV in adults after at least 2-years follow-up are presented in 
Table 4. The reported efficacy varies widely between 55-100%.8-19 However, this is probably due to 
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differences in inclusion criteria as the efficacy of ETV is also dependent on indication. The studies by 
Buxton et al. and Santamarta et al. presented outcomes in unselected adults with hydrocephalus, mostly 
caused by aqueduct stenosis or neoplasm. The proportion of patients remaining shunt-free were marginally 
lower in the study employing longer follow-up (73% vs. 80%), which supports our findings of late ETV 
failures.9, 12 It is well established that most ETV failures occur early, if at all.9, 12, 20, 21 As with all patients 
with hydrocephalus, long-term follow-up is often required either through annual clinic review or an open 
access emergency hydrocephalus clinic. In view of our findings, a strategy to discharge patients after 2 years 
of follow-up is feasible, but patients should be warned about the possibility of late failure and given rapid 
access to the hydrocephalus service in the event of symptom recurrence. Acute failure can occur and is 
recognized as potentially fatal.22 
A recently published study by Grand et al. included 243 patients in whom ETV was possible. After a mean 
follow-up period of 6 years, the authors reported ETV failure in 66 patients, of which 36 required a shunt 
procedure (85% shunt-free). However, it should be noted that there was a relatively high rate of parent 
refusal to further treatment and/or loss to follow-up. This was the case in 18 of the remaining 30 patients 
with ETV failure, such that the actual rate of ETV success was probably closer to about 78%.19  Our study 
further adds to the literature by presenting outcomes after a longer follow-up period and evaluating 
prognostic factors associated with ETV success.  
In cases of ETV failure, where symptoms re-occur, CSF flow studies are performed at our institution to guide 
management decisions. A further attempt at ventriculostomy is undertaken only where there is demonstrable 
impairment of flow through the fenestration site. In the present study, around one third of patients treated 
with an ETV required either an immediate shunt or redo procedure. Of the patients undergoing a redo 
procedure, 9 out of 15 (60%) remain shunt-free. Other studies that have presented results of repeat ETV 
procedures have found an even higher rate of success between 83-96% and a repeat procedure is therefore 
recommended where indicated.23, 24  
Complications 
Intra and post-operative complications were noted in 6% of patients in this study. This is similar to other 
reports, though higher rates (>10%) of complications have also been reported using the same surgical 
technique.9, 20, 25 The main intraoperative complication is haemorrhage, that can be severe and result in 
procedure abandonment. Recently, some authors have also reported outcomes with laser-assisted ETV, 
though complication rates appear to be higher than studies employing conventional techniques, at around 
10%.26, 27 Although not a complication per se, a minority of patients also harbour anatomical variants of the 
third ventricle floor, which preclude successful fenestration. Such patients are encountered very rarely 
however and we noted only two during the study period. 
Tumours 
Pineal and tectal tumours are especially prone to causing obstructive hydrocephalus and an endoscopic 
technique allows for concomitant tumour sampling and treatment of hydrocephalus. ETV is desirable for 
treatment of hydrocephalus given that most of these tumours are likely to be low-grade gliomas and non-
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curable, such that potential complications from shunt placement are difficult to justify. In the present study, 
ETV was successful in ~75-80% of tectal and pineal lesions, which represents an excellent rate of long-term 
control. The present study also builds on our previous work on tectal gliomas, recommending ETV as a 
primary treatment modality for these tumours.28 Studies have also presented favourable outcomes with pineal 
tumours. Chibbaro et al. presented their experience with ETV for posterior third ventricle and pineal region 
tumours, and reported that 100% of patients were shunt-free after 39 months mean follow-up.15 Other studies 
have found similar results.29 However, patients with caudal brainstem tumours may not do so favourably. 
Indeed, patients with cerebello-pontine angle tumours had a particularly high rate of ETV failure (40%) in 
the present study.  
Aqueduct stenosis and LOVA 
Aqueduct stenosis can occur in the primary form, where clinical features of hydrocephalus develop acutely 
in previously healthy adults. Alternatively, it can occur in children and adolescents, with insidious 
ventriculomegaly that usually manifests in adulthood.30 This latter syndrome (LOVA), is usually 
asymptomatic as a result of compensated CSF flow dynamics, though symptoms can develop.14 Long-term 
control of hydrocephalus induced by these pathologies was 80-90% in the present study and compares well 
to other studies.14, 18, 31 However, considerably lower rates of efficacy have also been reported. Tissel et al. 
deemed 9 out of 18 patients who underwent an ETV for aqueduct stenosis, to have an unsatisfactory outcome 
after 37 months mean follow-up. However, only 7 patients were further investigated and offered shunt 
placement, including one patient with blocked convexity CSF flow, despite slight clinical improvement and 
decreased ventricular size.8 The authors did not clarify why they investigated and offered further treatment to 
only a proportion of patients they deemed to have an unsatisfactory outcome. This limitation only partially 
explains their relatively poor outcomes, however.  
Other primary indications 
Other patient groups that benefited from primary ETV therapy included patients with Chiari type 1 
malformations. Our findings are again supported by other studies presenting outcomes after medium to long-
term follow-up with these patients.10 In one study, 5 out of 5 patients with Chiari-1 malformations remained 
shunt-free after 50 months mean follow-up, including one patient who underwent a successful repeat 
procedure. Complications were relatively high due to one transient wound-infection in the study. Our study 
was not sufficiently powered to convey data on the efficacy of ETV for indications such as NPH, though 
excellent medium to long-term outcomes have been reported.11, 13, 16 In one study, 86% of patients with NPH 
remained shunt-free during 78 months mean follow-up, though a significant proportion (>50%) of patients 
with unsatisfactory outcome refused further surgery.13 
ETV for shunt-failure (secondary ETV) 
The efficacy of ETV after shunt-failure was 59% in the present study, in which the majority of patients were 
offered ETV for mechanical shunt blockage. Furthermore, previous shunt was the only factor that influence 
outcome in this cohort of adults with ETV. Other studies have also reported a similarly low efficacy of ETV 
after shunt failure.17, 21, 32 Kulkarni et al. also recognised this negative prognostic factor in their description of 
the ETV success score, which awards a higher probability of success to patients who are shunt-naive at 
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presentation.6 The overall score itself was not found to influence survival in this cohort, and this is to be 
expected as it was primarily intended for paediatric patients. It is clear that patients with a prior shunt 
represent a select cohort that is more difficult to treat. Despite the relatively lower rate of long-term efficacy, 
patients presenting with shunt failure should be considered for ETV where appropriate, with vigilant clinical 
follow-up postoperatively.  
Limitations  
Limitations of the present study include its retrospective design and small patient numbers in some 
subcategories. Indeed, despite the current interest surrounding ETV for NPH, this could not be assessed with 
certainty due to limitations of sample size. In addition, we did not report on quality of life or symptom 
related outcomes, though arguably patients would be expected to re-present to our regional referral centre in 
the setting of recurrent symptoms. Our definition of ETV failure was based on symptomatic relapsed 
hydrocephalus that required a shunt. Other patient groups that could have arguably "failed" included patients 
who were successfully treated with a redo ETV procedure and remained shunt-free, which we regarded as a 
successful outcome. This approach could also have missed patients with asymptomatic, compensated 
hydrocephalus post-operatively.  
Conclusion 
In this study, we updated our ETV experience after long-term follow-up (median 112 months) in a cohort of 
190 adult patients with hydrocephalus of multiple aetiologies. ETV remains a safe (6% complication rate) 
and effective (73% shunt-free) procedure for obstructive hydrocephalus, with greater success rate when 
performed as a first-line intervention rather than after shunt failure. A successful ETV outcome was obtained 
in 139 patients (73%), which is lower than our previous report and highlights the occurrence of late failures. 
Although the majority (86%) of ETV failures occurred within 2 years of the procedure, late failures (>5 
years) were noted in three cases, including one patient who failed after 124 months follow-up. Although a 
strategy to discharge patients after 2 years of follow-up is feasible, patients should be warned about the 
possibility of late failure and given rapid access to the hydrocephalus service in the event of symptom 
recurrence. 
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Table and Figure legends 
Table 1. Overall ETV success rate in primary and secondary groups.  
Table 2. ETV success rates by subcategories of primary and secondary groups.  
Table 3. Actuarial rates of ETV survival. The proportion of patients remaining shunt-free was consistently 
higher in the primary ETV group.  
Table 4. ETV success rates in contemporary literature. Note that this table only includes those studies 
reporting after a follow-up of at least 2 years. AS = aqueduct stenosis; NPH = normal pressure 
hydrocephalus.  
Figure 1. T2 sagittal MRI showing third ventricle anatomy, in (A) normal; (B) hydrocephalus pre-
surgery; and (C) hydrocephalus post-ETV.  Open arrowheads show the tectal plate and aqueduct below.  Note 
in (B) the aqueduct is expanded indicating high pressure and in (C) the aqueduct is smaller following the 
ETV.   Closed arrowhead shows flow (low signal intensity) through the ventriculostomy in the third ventricle 
floor. 
Figure 2. ETV survival by group. The ETV survival time was longer in the primary ETV group (A) in 
entire cohort (p = 0.004) and, (B) in the cohort of patients with an ETV survival time of >24 months (p = 
0.022). 
Figure 3. ETV survival by aetiology. (A) In all patients. (B) In the primary ETV group. (C) In the 
secondary ETV group.  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Table 1 
  
Table 2 
Primary (%) Secondary (%) All patients
Successful 103 (80%) 36 (59%) 139
Failure 26 (20%) 25 (41%) 51
Total 129 61 190
Aetiology
ETV group
Primary Secondary
n Success rate, n (%) n Success rate, n (%)
Tumour 66 50 (76%) 8 6 (75%)
Third ventricle 
(including colloid cyst)
7 6 (86%) 4 2 (50%)
CP angle 10 6 (60%) 0 -
Posterior fossa 8 5 (63%) 2 2 (100%)
Tectal plate 13 10 (77%) 1 1 (100%)
Pineal 21 16 (76%) 1 1 (100%)
LOVA 24 20 (83%) 0 -
Aqueduct stenosis 9 8 (89%) 18 10 (56%)
Chiari malformation 19 17 (89%) 22 11 (50%)
Chiari 1 18 16 (89%) 22 11 (50%)
Chiari 2 1 1 (100%) 0 -
Other 11 9 (82%) 13 9 (69%)
NPH 2 1 (50%) 0 -
Post-infectious 0 - 4 1 (25%)
Post-haemorrhagic 2 2 (100%) 4 3 (75%)
Dandy-Walker 2 1 (50%) 0 -
Mechanical shunt blockage - - 52 32 (62%)
Shunt infection - - 9 4 (44%)
Table 3 
Table 4 
ETV survival 
(months)
Proportion remaining shunt-free
Primary group (%) Secondary group (%)
12 83 67
24 80 67
60 79 61
120 79 55
Study n Age, years 
(range)
Follow-up, 
months (range)
Complications Shunt-free (%) Patient group
Present study 190 43 (16-79) 112 (1-190) 6% 73% Unselected
Grand et al. 2016 [19] 243 51 (17-88) 72 (7-174) 4% 85 Unselected
Locatelli 2014 [18] 13 56.8 (22-72) 30.6 (3-52) 0% 100% AS
Al-Jumaily 2012 [14] 20 52 (17-78) 46 (6-80) 0% 90% LOVA
Chibbaro 2012 [15] 20 31(16-67) 39 (12-60) 10% 100% Tumours
Woodworth 2012 [17] 103 45 (±16) 60 (24-108) 2% 55% Secondary
Fountas 2012 [16] 7 72 (68-72) 36.7 (12-72) - 100% NPH
Gangemi 2008 [13] 110 67 (51-83) 78 (24-144) 6.4% 86% NPH
Santamarta 2005 [12] 66 53 (27-67) 69 (0-95) 9% 73% Unselected
Gangemi 2004 [11] 25 69 (53-75) 37 (20-84) 4% 84% NPH
Decq 2001 [10] 5 29.6 (18-46) 50.3 (14-109) 20% 100% Chiari-1
Buxton 2001 [9] 63 32 (17-77) 37 (0-84) 17.5% 80% Unselected
Tisell 2000 [8] 18 48 (17-80) 37 (14-66) - 61%* AS
A	 B	 C	
Figure	1.	
T2	sagi.al	MRI	showing	third	ventricle	anatomy,	in	(A)	normal;	(B)	hydrocephalus	
pre-surgery;	and	(C)	hydrocephalus	post-ETV.		Open	arrowheads	show	the	tectal	
plate	and	aqueduct	below.		Note	in	(B)	the	aqueduct	is	expanded	indicaMng	high	
pressure	and	in	(C)	the	aqueduct	is	smaller	following	the	ETV.			Closed	arrowhead	
shows	ﬂow	(low	signal	intensity)	through	the	ventriculostomy	in	the	third	
ventricle	ﬂoor.	
Figure 2
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